BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

→ BioN­Tech is buy­ing Mab­Vax’s labs $MB­VX and a clin­i­cal as­set out of bank­rupt­cy as the Ger­man mR­NA com­pa­ny es­tab­lish­es a satel­lite op­er­a­tion in San Diego. The biotech, which has ev­i­dent­ly been kick­ing around a mon­ster IPO, ac­quired the bank­rupt op­er­a­tion’s lead can­di­date, MVT-5873, “as well as oth­er pre-clin­i­cal an­ti­body as­sets to ex­pand and com­ple­ment its ex­ist­ing an­ti­body port­fo­lio.” That lead Phase I pro­gram is de­scribed as an IgG1 mon­o­clon­al an­ti­body tar­get­ing sia­lyl Lewis A (SLeA), “an epi­tope ex­pressed in pan­cre­at­ic and oth­er GI can­cers that plays a role in tu­mor ad­he­sion and metas­ta­sis for­ma­tion.” No terms were giv­en, but BioN­Tech made clear in its state­ment that they plan to use the new base to help with their clin­i­cal de­vel­op­ment plans in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER